Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook



 

Fourteen genes predict cancer response to therapy

05 September 2016

By Meetal Solanki

Appeared in BioNews 867

A major study into cancer has uncovered 14 genes which could predict how a patient will respond to tumour treatments, particularly chemotherapy and radiation therapy.

The discovery of these specific biomarkers may allow clinicians to tailor treatment for the patient, and be crucial in helping some patients avoid cancer treatments which can cause undesirable effects.

'The history of cancer treatment is filled with overreaction,' said principal investigator Professor Gary Karpen, a senior scientist at the University of California, Berkeley in the USA. 'It is part of the ethics of cancer treatment to err on the side of overtreatment, but these treatments have serious side effects associated with them.'

Currently, doctors rely on information such as the stage and grade of cancer tumours to decide upon suitable treatment. However, there has been no reliable way to predict at an early stage of cancer development how patients will respond to therapy.

Researchers at the Lawrence Berkeley National Laboratory in California screened public datasets about clinical cancer tumour samples for 31 genes associated with chromosomal instability. Overexpression of these genes is linked to chromosomal instability, where chromosomes break during cell division, has long been recognised as a hallmark of cancer.

Yet although these genes are associated with poor patient survival, they are also related to a more positive response to gene-damaging treatments like chemotherapy and radiation therapy.

Conversely, patients with lower expression may have a better prognosis but find these therapies as ineffective.

The researchers identified 14 genes which were consistently overexpressed in cancer tissue. These results were derived from thousands of samples from at least a dozen different types of cancer, provided by the National Center for Biotechnology Information, the Broad Institute and other institutions.

It is hoped that this research may pave the way for more precision medicine and make it easier for future doctors to choose appropriate therapies for patients.

Dr Karpen explained: 'Chromosome instability is such a basic part of how cancer progresses that this approach gives us an opportunity to use the score in many different cancer types such as lung and breast, and by providing information to patients about the choices they might make with respect to therapy, we think this could make a very important contribution to the field.'

Further investigation and validation of findings will have to be done before it can be applied to the clinical field. The researchers note that they found no link between very high levels of genome instability and improved patient survival without adjuvant treatments, and so will need to establish a reliable threshold of genome instability so that doctors and patients can make informed decisions.

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

04 December 2017 - by Theofanis Michailidis 
The US Food and Drug Administration has approved a test which can detect cancer-causing mutations in 324 genes...
30 May 2017 - by Shaoni Bhattacharya 
The first cancer drug based on a specific genetic feature has been approved by the US drugs regulator...
28 November 2016 - by Anna Leida 
Having two copies of the X chromosome may help explain why females get cancer less often than males, according to new research...

30 August 2016 - by Ebtehal Moussa 
A new genetic test could predict which patients with early-stage breast cancer patients would benefit from chemotherapy...
13 June 2016 - by Rachel Reeves 
Genetic sequencing leading to targeted treatment significantly improves cancer patient outcomes in early-stage clinical trials, according to a study...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation